The National Cancer Database (NCDB) is a hospital-based registry that captures an estimated 73.7% of newly diagnosed cancers in the United States and supports thousands of outcomes studies that influence oncologic practice. This updated review characterizes structural revisions, variable-level changes, and policy updates to the NCDB over the past decade, with emphasis on implications for outcomes-based research.
The authors conducted a narrative review of annual NCDB data dictionary revisions, American College of Surgeons bulletins, and internal program updates in collaboration with NCDB leadership. Structural modifications, additions to variables, and policy changes affecting data capture, follow-up, staging, and accessibility were systematically summarized. The review synthesizes these source documents to describe how the NCDB has evolved and what investigators must consider when using the database for research.
The NCDB now includes data from 1,413 Commission on Cancer–accredited hospitals and comprises more than 55 million records. Since 2020 the Rapid Cancer Reporting System has enabled near-real-time monthly submissions, a structural change intended to increase the timeliness of case capture and the currency of analytic data. The NCDB continues to serve as a large, national resource for outcomes research but has adopted procedures that change both the speed and scope of data availability.
Over the past decade the NCDB has introduced several variable refinements and new data elements to increase granularity and policy relevance. Important changes documented in the review include:
These changes increase clinical detail but also create temporal heterogeneity as variables mature or are phased in across calendar years.
Policy changes intended to improve analytic timeliness include reductions in data embargo periods. The embargo for survival data was reduced from 5 years to 3 years; embargo periods for other variables were reduced to 2 years. The NCDB also instituted a limit on follow-up: beginning January 1, 2022, follow-up is recorded for up to 15 years. Investigators relying on long-term survival or recurrence data must account for this truncation when designing studies and interpreting trends across cohorts assembled before and after this change.
Staging in the NCDB has transitioned over recent years. The AJCC eighth edition staging was implemented in January 2018, and a rollout of the ninth edition is ongoing. Such staging transitions alter stage group assignments, tumor descriptors, and potentially inclusion criteria for stage-specific analyses. Studies that span edition changes must explicitly address staging harmonization or stratify analyses by edition to avoid misclassification and bias when comparing outcomes across time periods.
The NCDB’s movement toward more granular and contemporary data capture offers expanded research opportunities, including policy-relevant analyses (for example, Medicaid expansion) and investigations tied to pandemic-era effects. However, the review emphasizes several analytic considerations investigators must manage:
The review notes that investigators must remain mindful of registry-specific limitations when interpreting NCDB-derived results. Examples highlighted include potential biases related to hospital accreditation and case mix, changes in data capture practices over time, and incomplete or phased-in variables. The authors advise that studies using the NCDB explicitly report how they handled staging transitions, variable maturation, follow-up limits, and any analytic strategies used to mitigate registry-specific bias. Where the source did not report additional methodological recommendations or validation metrics, those details were not provided in the review.
The NCDB has evolved to provide more granular, contemporary, and policy-relevant data while maintaining broad national coverage. Structural changes such as the Rapid Cancer Reporting System, shortened embargoes, and new clinical and policy variables increase the database’s utility but also introduce temporal and methodological complexities. Investigators conducting outcomes-based research with NCDB data must account for staging transitions, variable availability by year, follow-up truncation, and registry-specific biases to ensure valid interpretation of findings.